Sokhna Aissatou Touré

Dr. Sokhna Aissatou Touré

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
BFBlaise Felix Faye
Blaise Felix Faye
NDNata Dieng
Nata Dieng
MSMoussa Seck
Moussa Seck
MGMacoura Gadji
Macoura Gadji
YGYoussou Bamar Gueye
Youssou Bamar Gueye
SDSaliou Diop
Saliou Diop

24 April 2017 in BMC Hematology
Verified
Journal Article
Open access
PDF file
MSMoussa Seck
Moussa Seck
ASAloïse Sagna
Aloïse Sagna
MGMame Sokhna Guéye
Mame Sokhna Guéye
BFBlaise Félix Faye
Blaise Félix Faye
DSDiariétou Sy
Diariétou Sy
SDSaliou Diop
Saliou Diop
Circumcision in hemophiliacs is a delicate surgery because of bleeding risks that could be avoided by adequate substitution of coagulation factor. This practice is very challenging in countries where anti hemophilic treatment is inaccessible. The study aimed to evaluate a circumcision protocol in hemophilia A using low quantities of factor concentrates. This prospective study included 26 hemophiliacs A who underwent circumcision in 2014. Medical treatment protocol using low quantity of factor concentrates was drafted by physicians of the Hemophilia Treatment Center and the surgical protocol by experienced surgeons. Assessment criteria were: number of hospitalization days, number of exposure days to factor concentrates, delay to healing and occurrence of bleeding events. Mean age was 9.6 years (1–30). Hemophiliacs patients were classified as severe (n = 8), moderate (n = 9) and mild form (n = 9). Mean number of exposure days to factor VIII concentrates was 6.9 days (5–12) in children and 10.75 days (7–16) in adults (p = 0.0049); mean number of hospitalization days was 3.68 days (2–10) in children and 13.5 days (13–15) in adults (p = 0.0000); delay to healing was 26.47 days (20–35) in children and 25.25 days (22–30) in adults (p = 0.697); five haemophiliacs (19.2%) presented bleeding events after the circumcision. The mean amount of FIII concentrates used per patient was 1743 IU (810–2340). The study shows treatment protocol using low quantity of factor concentrates is efficient in hemophilia patients who underwent circumcision.

20 March 2022 in Hematology
Verified
Journal Article
Open access
STSokhna Aissatou Touré
Sokhna Aissatou Touré
MSMoussa Seck
Moussa Seck
DSDiariatou Sy
Diariatou Sy
EBElimane Seydi Bousso
Elimane Seydi Bousso
BFBlaise Félix Faye
Blaise Félix Faye
SDSaliou Diop
Saliou Diop
Life-threatening bleeding (LTB) is one of the major complications of hemophilia with a high risk of mortality.

15 May 2022 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
STSokhna Aissatou Touré
Sokhna Aissatou Touré
MSMoussa Seck
Moussa Seck
DSDiariatou Sy
Diariatou Sy
ASAlioune Badara Senghor
Alioune Badara Senghor
BFBlaise Félix Faye
Blaise Félix Faye
SDSaliou Diop
Saliou Diop
In Africa, where access to diagnosis and treatment of hemophilia is the lowest in the world, prophylaxis is rarely used in preference to on-demand treatment. There are limited data of prophylaxis treatment from sub-Saharan Africa. The aim of this study was to evaluate clinical outcomes and inhibitor development in people with hemophilia receiving low-dose prophylaxis (LDP) in a sub-Saharan African setting. We conducted a three-year prospective study. A once or twice weekly prophylaxis regimen of 25 IU/kg of rFVIIIFc or 30 IU/kg of rFIXFc was given to Hemophilia A and B, respectively. We evaluated clinical outcomes and inhibitors occurrence, determined by screening and titration using the Nijmegen technique. A total of 15 patients were included in the LDP regimen. The mean age was 6.3 years (1.5 - 10). A significant reduction was noted in the annualized bleeding rate, from 7.53 to 1.33 (p = 0.0001); the annualized joint bleeding rate passed from 3.6 to 1.4 (p = 0.001) and the proportion of severe bleeding, from 86.1% to 16.7% (p = 0.0001). The Hemophilia Joint Health Score (HJHS) moved from 9.6 to 3.4 (p = 0.0001) and the Functional Independence Score in Hemophilia (FISH) improved from 25.8 to 30.9 (p = 0.0001). School absenteeism decreased from 7.33% to 2.59%. Adherence to prophylaxis was 89.5% versus 60%. Consumption was 580 IU/kg/year versus 1254.6 IU/kg/year before and after prophylaxis, respectively. Incidence of inhibitors was 23% (3 /13 HA). The LDP in Hemophilia improves the clinical outcome without a surplus risk of inhibitor development. Using extended half-life clotting factor concentrates (CFCs) is better for prophylaxis in resource-limited countries, as they allow better compliance in treatment.

1 January 2024 in Advances in Hematology
Verified
Journal Article
Open access
PDF file
MSMoussa Seck
Moussa Seck
MDMaureen Adéniké Dabo
Maureen Adéniké Dabo
EBElimane Seydi Bousso
Elimane Seydi Bousso
MKMohamed Keita
Mohamed Keita
STSokhna Aissatou Touré
Sokhna Aissatou Touré
SDSaliou Diop
Saliou Diop
Objectives. The aim of this study was to describe the morbidity and mortality of homozygous sickle cell disease after the age of 40. Methods. This was a cohort study of 209 patients followed from 1994 to 2022. All hemoglobin electrophoresis‐confirmed SS sickle cell patients over 40 years were included. A descriptive study of epidemiological, diagnostic, therapeutic, and evolutionary data was used to assess morbidity and mortality. Results. Sex ratio (M/F) was 0.6. Median age was 47 (41–75). According to morbidity, 95.1% had less than 3 vaso‐occlusive crises/year. Acute anemia was the most frequent complication (52.63%). Chronic complications were noted in 32.5%. At diagnosis, mean hemoglobin was 8.1 g/dl ± 1.9, HbS was 86.5 ± 10, and HbF was 9.4 ± 7.6. Number of patients transfused was 66%. We noted that 8.1% of patients died, 29.2% were lost to follow‐up, and 62.7% were still being followed up. The risk factors identified for death were geographical origin, comorbidity, high HbS, low HbF, and thrombocytosis. Conclusion. This study shows that homozygous SCD is increasingly becoming an adult disease and that it can be carried into old age in Africa. Advanced age over 40 is marked by an upsurge in chronic complications, making it essential to set up a screening program and to organize multidisciplinary follow‐up.

18 October 2024 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
ADAlioune Badara Diallo
Alioune Badara Diallo
MSMoussa Seck
Moussa Seck
MKMohamed Keita
Mohamed Keita
STSokhna Aissatou Touré
Sokhna Aissatou Touré
EBElimane Seydi Bousso
Elimane Seydi Bousso
SDSali̇oU Diop
Sali̇oU Diop
Background/aim: The evolution of sickle cell disease (SCD) is marked by the occurrence of painful episodes linked to the obstruction of micro-vessels by sickle cells, known as vaso-occlusive crises (VOC). The aim of our work was to report the practical aspects of the management of acute pain in adults with SCD. Recommendations based on these practices are also provided.Materials and methods: We conducted a prospective, cross-sectional, descriptive and analytical study over a 4-month period of all sickle cell patients admitted to emergency departments for VOC. The parameters studied were sociodemographic, clinico-biological, therapeutic and evolutionary.Results: 118 cases of VOC were identified, representing a prevalence of 78.14% of sickle cell emergencies. The mean age of the patients was 28.41 years. The SS sickle cell phenotype accounted for 86.61% of cases. Osteoarticular pain was the reason for admission in 88.39% of cases; it was located in the lower limbs in 39.08% of cases and in the spine in 27.1% of cases. Pain intensity was moderate in 6.25% of cases, intense in 31.25% and unbearable in 55.55%. Multimodal analgesia was the most commonly used treatment method, combining levels 1 and 2 (74.31%) and levels 1 and 3 (8.25%). The mean dose of morphine administered was 17.14 mg when morphine alone was prescribed for titration, 13.57 mg when paracetamol and morphine were combined, and 15.83 mg when nefopam and morphine were combined. Clinical outcome was favourable in 68.87% of cases.Conclusion: We noticed a wide variability in the modalities of analgesic treatment of sickle cell VOC. These variations reflect different views on the appropriateness of opioids. This study highlights the efficacy of multimodal analgesia in the management of acute pain in patients with SCD, particularly with regard to morphine sparing. Context-specific recommendations will be needed to harmonize practices.